Rapport Therapeutics, Inc. Common Stock
RAPP
Updated: 23/09/2026, 13:06:34
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
No summaries found.
- Share price
- $41.47
- Market cap
- $1.98B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Abraham N. Ceesay
- Employees
- 84
- IPO date
- 07/06/2024
- Beta
- 1.026
- Last dividend
- $0.00
- Day range
- $37.98 – $41.55
- 52-week range
- $23.75 – $52.93
- 1-day performance
- 4.56%
- 1-year performance
- 74.61%
- Current drawdown (1Y)
- -21.65%
- CIK
- 0002012593
- CUSIP
- 75383L102
- ISIN
- US75383L1026
- Created
- 07/12/2025, 13:55:04
- Last update
- 23/09/2026, 13:06:34
Track Rapport Therapeutics, Inc. Common Stock with an AI analyst
See which prediction-market events move RAPP, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 17:48:31
Modalités de mise à disposition du rapport financier annuel 2025
GlobeNewsWire • STOCK • 30/04/2026, 17:11:00
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
GlobeNewsWire • STOCK • 30/04/2026, 13:45:00
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
GlobeNewsWire • STOCK • 21/04/2026, 18:30:00
CRCAM Toulouse 31 - Rapport financier annuel 2025
GlobeNewsWire • STOCK • 30/03/2026, 07:28:00
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Zacks Investment Research • STOCK • 26/03/2026, 14:00:37
Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript
Seeking Alpha • STOCK • 17/03/2026, 16:32:18
Mise à disposition des éléments préparatoires à l'AG du 27/03/2026 - Rapport Financier Annuel 2025
GlobeNewsWire • STOCK • 12/03/2026, 04:00:00
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
GlobeNewsWire • STOCK • 09/03/2026, 08:00:00